Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminated
NCT03452137Phase 3Updated Oct 9, 2024
Sponsor: Hoffmann-La Roche
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
United States, Australia, Belgium, Brazil, Canada +18 more
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaTerminated
NCT05315713Phase 1, Phase 2Updated Oct 4, 2024
Sponsor: Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
United States, Australia, Belgium, Canada, Germany +1 more
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung TransplantationCompleted
NCT00227370Phase 3Updated Oct 4, 2024
Sponsor: Duke University
Cytomegalovirus Infections
United States
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompleted
NCT03635489Phase 3Updated Oct 3, 2024
Sponsor: Hoffmann-La Roche
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
China
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's DiseaseCompleted
NCT04000594Phase 1Updated Oct 3, 2024
Sponsor: Hoffmann-La Roche
Huntingtons Disease
Netherlands, United Kingdom
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaCompleted
NCT03875079Phase 1Updated Oct 3, 2024
Sponsor: Hoffmann-La Roche
Metastatic Melanoma
United States, Australia, Belgium, Canada, France +2 more
Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)Recruiting
NCT04611867NAUpdated Oct 2, 2024
Sponsor: Inna Chen, MD
Pancreatic Cancer · Lung Cancer, Nonsmall Cell
Denmark
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompleted
NCT02389842Phase 1Updated Sep 26, 2024
Sponsor: Royal Marsden NHS Foundation Trust
Advanced Solid Tumours · Breast Cancer
United Kingdom
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic RetinopathyCompleted
NCT04265261Phase 2Updated Sep 25, 2024
Sponsor: Hoffmann-La Roche
Diabetic Retinopathy
United States, Australia, Poland, Puerto Rico, Slovakia +2 more
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemCompleted
NCT05275010Phase 1Updated Sep 23, 2024
Sponsor: Hoffmann-La Roche
Healthy Male Subjects
Australia, New Zealand
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.Withdrawn
NCT06099418Phase 2Updated Sep 20, 2024
Sponsor: Nykode Therapeutics ASA
HPV-Related Cervical Carcinoma · HPV-Related Malignancy · Cervical Cancer
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² StudyRecruiting
NCT06105177N/AUpdated Sep 19, 2024
Sponsor: Catharina Ziekenhuis Eindhoven
Lung Cancer
Netherlands
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.Completed
NCT05924243Phase 1Updated Sep 19, 2024
Sponsor: Hoffmann-La Roche
Parkinson Disease
United States, Netherlands, United Kingdom
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell LymphomaRecruiting
NCT04332822Phase 3Updated Sep 19, 2024
Sponsor: Nordic Lymphoma Group
DLBCL · Diffuse Large B Cell Lymphoma
Australia, Denmark, Finland, Italy, New Zealand +2 more
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruiting
NCT06342037Phase 2Updated Sep 19, 2024
Sponsor: The Netherlands Cancer Institute
Metastatic Breast Cancer
Netherlands
Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart FailureRecruiting
NCT04437628N/AUpdated Sep 19, 2024
Sponsor: Wonju Severance Christian Hospital
Heart Failure
South Korea
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORSActive Not Recruiting
NCT06597045N/AUpdated Sep 19, 2024
Sponsor: NHS Greater Glasgow and Clyde
Cancer · Cardiotoxicity · Atherosclerotic Disease
United Kingdom
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerCompleted
NCT03598270Phase 3Updated Aug 30, 2024
Sponsor: Grupo Español de Investigación en Cáncer de Ovario
Recurrent Ovarian Carcinoma
Belgium, France, Germany, Italy, Spain
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)Completed
NCT02550652Phase 2Updated Aug 27, 2024
Sponsor: Hoffmann-La Roche
Lupus Nephritis
United States, Argentina, Brazil, Colombia, Costa Rica +7 more
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.Active Not Recruiting
NCT03375437NAUpdated Aug 26, 2024
Sponsor: Centre Leon Berard
Soft Tissue Sarcoma · Advanced Cancer · Metastatic Cancer
France
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaTerminated
NCT05219513Phase 1Updated Aug 23, 2024
Sponsor: Hoffmann-La Roche
Lymphoma, Non-Hodgkin
United States, Australia, Denmark, France, Italy +1 more
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerTerminated
NCT03498716Phase 3Updated Aug 21, 2024
Sponsor: Hoffmann-La Roche
Triple Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast CancerCompleted
NCT02595762N/AUpdated Aug 19, 2024
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Cyprus, Greece
An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their FamiliesCompleted
NCT04723693N/AUpdated Aug 19, 2024
Sponsor: Haemnet
Hemophilia A With Inhibitor
United Kingdom
Primary Operation in SYnchronous meTastasized InVasivE Breast CancerCompleted
NCT01015625NAUpdated Aug 19, 2024
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Austria

Previous page Next page